G Atabay

Ege University, İzmir, Izmir, Turkey

Are you G Atabay?

Claim your profile

Publications (8)30.56 Total impact

  • H Töz · S Sen · M Seziş · S Duman · M Ozkahya · S Ozbek · C Hoşcoşkun · G Atabay · E Ok
    [Show abstract] [Hide abstract]
    ABSTRACT: Acute and chronic lesion scores on renal allograft protocol biopsies may predict long-term graft function. The aim of this study was to compare the effects of tacrolimus (Tac) and cyclosporine microemulsion (CsA) based immunosuppressive protocols using protocol biopsies from well-functioning renal allografts. 35 consecutive renal transplant patients were randomized to Tac (n: 17) versus CsA (n: 18) treatment arms. Patient age and sex, donor type and age, histocompatibility, cold ischemia time and prior delayed graft function were similar between the two groups. Treatment protocol consisted of prednisolone, azathioprine and Tac or CsA. Biopsies performed on the third, sixth and twelfth months were blindly evaluated by the same pathologist. The incidences of acute rejection (AR) episodes among CsA vs Tac groups were 33% vs 29%, respectively (NS). The Creatinine level was lower in Tac than CsA, although it was not significant (Table). Subclinical AR and subclinical chronic allograft nephropathy were detected on protocol biopsies in 3 (2 CsA, 1 Tac) and 12 (7 CsA, 5 Tac) patients, respectively. Acute lesion score at the third month PBx was significantly lower in the Tac group (p < 0.05). Chronic lesion scores in all biopsies were lower in the Tac group, although not significantly. The protocol biopsy findings suggest that graft injury may be less pronounced among the Tac group.
    No preview · Article · Jan 2004 · Transplantation Proceedings
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Peritoneal fibrosis (PF) is one of the most serious causes of failure in continuous ambulatory peritoneal dialysis (PD). Although the underlying mechanism responsible for the genesis of PF is still unknown, transforming growth factor beta (TGFbeta1) has been shown to be associated with PF. Angiotensin converting enzyme inhibitors have been shown to prevent the stimulating effect of growth factors. The aim of the present study was to investigate the effect of enalapril on peritoneal function and morphology in a rat model of experimental PF. Twenty-one albino Wistar rats were divided into three groups: (1) the control group (C) received 10 mL isotonic saline intraperitoneally (i.p.), (2) the dextrose (Dx) group 10 mL 3.86% dextrose PD solution i.p., and (3) the enalapril-treated group (ENA) 10 cc 3.86% dextrose PD solution i.p. plus 100 mg/L enalapril in drinking water. After 4 weeks, a 1-hour peritoneal equilibration test was performed with 20 mL 2.27% dextrose PD solution. Dialysate-to-plasma urea ratio (D/P urea), glucose reabsorption (D1/D0 glucose), ultrafiltration (UF) volume, and levels of dialysate protein, TGFbeta1, and cancer antigen 125 (CA125) were determined. The parietal peritoneum was evaluated histologically by light microscopy. Administration of enalapril resulted in preserved UF (-0.2 +/- 0.7 mL vs 1.7 +/- 0.3 mL, p < 0.05), protein loss (2.3 +/- 0.5 g/L vs 1.6 +/- 0.2 g/L, p > 0.05), and peritoneal thickness (77 +/- 7 microns vs 38 +/- 5 microns, p < 0.001). D/P urea increased significantly in the Dx group (p< 0.05). Both higher levels of TGFbeta1 (undetectable vs 298 +/- 43 pg/mL, p < 0.001) and lower levels of CA125 in dialysate effluent (0.94 +/- 0.5 U/L vs 0.11 +/- 0.1 U/L, p > 0.05) were determined in the Dx group. These findings show that peritoneal morphology and function tests were dramatically deranged in the Dx group. The same properties were partially preserved in the ENA group. The production of TGFbeta1 was significantly reduced but peritoneal thickness was not completely inhibited. In conclusion, by inhibiting the production of TGFbeta1, enalapril can preserve peritoneal histology, peritoneal function, and remodeling of mesothelial cells.
    Full-text · Article · Mar 2001 · Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis
  • Ali Çelik · Ercan Ok · A Unsal · H Töz · G Atabay

    No preview · Article · Dec 2000 · Nephron
  • Source
    T Camsari · C Cavdar · B Yemez · M Ozkahya · G Atabay · T Alkin · F Akçiçek

    Full-text · Article · Nov 1999 · Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis
  • F Akcicek · M Ozkahya · M Cirit · E Ok · A Unsal · H Toz · A Celik · G Atabay · A Basci
    [Show abstract] [Hide abstract]
    ABSTRACT: Some chronic renal failure patients respond poorly to recombinant human erythropoietin (rHuEPO). In continuous ambulatory peritoneal dialysis (CAPD) patients, such a poor response may indicate inadequate dialysis or low body iron stores. To correct iron deficiency, once-a-week intravenous iron supplementation is recommended. However, hemodialysis patients receive iron supplements three times a week. This study was designed to compare the efficacy of iron supplementation between once-weekly and twice-weekly regimens. In both groups, rHuEPO doses were similar. Seventeen CAPD patients were studied. All had hemoglobin levels less than 10 g/dL. Ten patients were given 100 mg intravenous iron once weekly, and 7 were given 50 mg intravenous iron twice weekly until a total iron dose of 600 mg was achieved (stage I). The patients were crossed over to receive another 600 mg iron (stage II). Hematocrit increased significantly in patients receiving twice-a-week iron supplementation (+3.8% and 6%) compared to those receiving once-a-week iron supplementation (+1.3% and 1.4%) during stages I and II. The ferritin levels were not different between the groups. In conclusion, rHuEPO is more effective when administered with intravenous iron.
    No preview · Article · Feb 1997 · Advances in peritoneal dialysis. Conference on Peritoneal Dialysis
  • F Akçiçek · E Ok · S Duman · S Kürsad · A Unsal · M Alev · G Atabay · A Basçi
    [Show abstract] [Hide abstract]
    ABSTRACT: We compared the lipid-lowering effects of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, and gemfibrozil, a fibric acid derivative, in 22 continuous ambulatory peritoneal dialysis patients whose serum total cholesterol and/or triglyceride levels were > or = 220 mg/dL after a standard diet for six months. The study group was first treated with gemfibrozil (600 mg/b.i.d.) for three months (stage 1). After a wash-out period of two months, during which no treatment was given, all of the patients became hyperlipidemic again and, therefore, were given simvastatin (10 mg/day) for three months (stage 2), which was followed by another two-month wash-out period. A control group, which served to evaluate the natural progression of pharmacologically untreated dyslipidemia, was followed during the same period. Blood determinations of triglyceride, total cholesterol, and high-density lipoprotein (HDL) cholesterol were performed after each step. Low-density lipoprotein (LDL) cholesterol and HDL ratio were calculated from the measured values. Both gemfibrozil and simvastatin improved all parameters of the lipid profile, but the effect of simvastatin was better than that of gemfibrozil (-69 vs -39 mg/dL for triglyceride and -95 vs -64 mg/dL for cholesterol), while their actions on LDL and HDL cholesterol were of equal magnitude. Two months after discontinuation of simvastatin, significant decreases of total cholesterol (-46 mg/dL) and triglyceride (-60 mg/dL) were still present, while these values had returned to pretreatment levels after stopping gemfibrozil. The HDL ratio remained markedlyhigher (p < 0.05) during the wash-out period after simvastatin, while it decreased to pretreatment values after gemfibrozil was stopped. The lipid profile of the control group did not change during the follow-up. Both drugs were well tolerated, and no serious side effects occurred.
    No preview · Article · Feb 1996 · Advances in peritoneal dialysis. Conference on Peritoneal Dialysis

  • No preview · Article · Feb 1994 · Nephron
  • [Show abstract] [Hide abstract]
    ABSTRACT: SUMMARY In this study, the frequency of crescentic glomerulonephritis(GN) and the clinical outcome of the patients with crescentic GN were evaluated retrospectively among 532 renal biopsies performed between January 1990 and January 1996 in our unit. Crescentic GN was determined in 23 cases(4.3%); 18 of them were primary crescentic GN( Type I in 2, Type II in 10, Type III in 6), while 5 were secondary crescentic GN. Sixteen of 23 patients whose mean creatinin levels were 7.9±4.2 mg/dl (1.5-16.6) at the first admission, dialysis requirement occurred during hospitalization period. Pulse steroid was applied in 16 patients, pulse steroid and oral cyclophosphamide in 4, pulse steroid and plasmapheresis in 2, plasmapheresis and pulse cyclophosphamide in 1. In 10 cases(43%), initial response to the therapy was obtained, but end-stage renal disease developed in 6 of them in 1 year despite initial good response. Creatinine levels at the first examination and the percentage of crescent in the biopsies were significantly higher in the patients who do not show response to the therapy than those of the patients with initial response. At the end of follow-up period of mean 32±14 months, 17 of 20 surviving patients were on renal replacement therapy(14 on dialysis, 3 on renal transplantation), 3 had stable renal function.
    No preview · Article ·